Add to ORKGCopyright © 2014 Masahisa Hemmi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Few of the vaccines in current use can induce antigen- (Ag-) specific immunity in bothmucosal and systemic compartments. Hence
Recombinant adenovirus (Ad) vectors elicit potent transgene product-specific T and B cell responses....
Copyright © 2015 Megha S. Nivsarkar et al. This is an open access article distributed under the Crea...
A Phase I trial conducted in 2009–2010 demonstrated that oral vaccination with a replica-tion compet...
Recombinant human adenovirus serotype 5 (HAd5V) vectors are gold standards of T-cell immunogenicity ...
Copyright © 2012 Violette Dirix et al. This is an open access article distributed under the Creative...
Copyright © 2013 B. J. Sedgmen et al. This is an open access article distributed under the Creative ...
In this study, we compared adenoviral vaccine vectors with the capacity to induce equally potent imm...
Immune responses directed against viral capsid pro-teins constitute a main safety concern in the use...
Adeno-associated virus (AAV) vectors are widely used in clinical gene therapy to correct genetic dis...
Recombinant adenovirus administration gives rise to transgene-independent effects caused by the abil...
Despite the rapid progress in the development of novel adop-tive T-cell therapies, the clinical bene...
A major goal in developing protective immune responses is to obtain robust CD8 T cell ex-pansion, ef...
This article is made available for unrestricted research re-use and secondary analysis in any form o...
The failure to mount effective immunity to virus variants in a previously virus-infected host is kno...
Contains fulltext : 89352.pdf (publisher's version ) (Closed access)T cell competi...
Recombinant adenovirus (Ad) vectors elicit potent transgene product-specific T and B cell responses....
Copyright © 2015 Megha S. Nivsarkar et al. This is an open access article distributed under the Crea...
A Phase I trial conducted in 2009–2010 demonstrated that oral vaccination with a replica-tion compet...
Recombinant human adenovirus serotype 5 (HAd5V) vectors are gold standards of T-cell immunogenicity ...
Copyright © 2012 Violette Dirix et al. This is an open access article distributed under the Creative...
Copyright © 2013 B. J. Sedgmen et al. This is an open access article distributed under the Creative ...
In this study, we compared adenoviral vaccine vectors with the capacity to induce equally potent imm...
Immune responses directed against viral capsid pro-teins constitute a main safety concern in the use...
Adeno-associated virus (AAV) vectors are widely used in clinical gene therapy to correct genetic dis...
Recombinant adenovirus administration gives rise to transgene-independent effects caused by the abil...
Despite the rapid progress in the development of novel adop-tive T-cell therapies, the clinical bene...
A major goal in developing protective immune responses is to obtain robust CD8 T cell ex-pansion, ef...
This article is made available for unrestricted research re-use and secondary analysis in any form o...
The failure to mount effective immunity to virus variants in a previously virus-infected host is kno...
Contains fulltext : 89352.pdf (publisher's version ) (Closed access)T cell competi...
Recombinant adenovirus (Ad) vectors elicit potent transgene product-specific T and B cell responses....
Copyright © 2015 Megha S. Nivsarkar et al. This is an open access article distributed under the Crea...
A Phase I trial conducted in 2009–2010 demonstrated that oral vaccination with a replica-tion compet...